Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT · IEX Real-Time Price · USD
0.360
-0.014 (-3.64%)
Jul 22, 2024, 10:07 AM EDT - Market open
Purple Biotech Employees
Purple Biotech had 20 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
$938,200
Market Cap
13.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Novo Integrated Sciences | 230 |
Ontrak | 104 |
STRATA Skin Sciences | 99 |
Check-Cap | 85 |
Aptose Biosciences | 36 |
Addex Therapeutics | 23 |
NEXGEL | 19 |
NeuroSense Therapeutics | 18 |
PPBT News
- 12 days ago - Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 - GlobeNewsWire
- 19 days ago - Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewsWire
- 21 days ago - Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds - GlobeNewsWire
- 25 days ago - Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit - GlobeNewsWire
- 7 weeks ago - Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Purple Biotech Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting - GlobeNewsWire
- 4 months ago - Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology - GlobeNewsWire